GURU.Markets stock price, segment price, and overall market index valuation
The company's share price CRVS
Corvus Pharmaceuticals is a biotech company developing cancer immunotherapy drugs. Its stock price is highly volatile and driven by news about clinical trials. The chart reflects investor hopes for the development of a new generation of cancer drugs.
Share prices of companies in the market segment - Cancer lymphonodes
Corvus Pharmaceuticals is a biopharmaceutical company developing small-molecule drugs that target the immune system for the treatment of cancer. We classify it in the Lymph Node Cancer sector. The chart below shows the overall dynamics of this highly specialized oncology segment.
Broad Market Index - GURU.Markets
Corvus Pharmaceuticals is an oncology company developing next-generation immunotherapy drugs. As an innovator in this field, it is included in our GURU.Markets index. The chart below shows the overall market trend. See how Corvus shares compare to sentiment in the biotech sector.
Change in the price of a company, segment, and market as a whole per day
CRVS - Daily change in the company's share price CRVS
The volatility of Corvus Pharmaceuticals, an oncology company, reflects the high risks of the biotech sector. Change_co is an immediate reaction to news about clinical trials. This indicator forms the basis for analysis of the immunotherapy sector using System.GURU.Markets tools.
Daily change in the price of a set of shares in a market segment - Cancer lymphonodes
Corvus Pharmaceuticals, Inc. is an oncology company. This chart demonstrates the extreme volatility of the biotech sector. Comparison with CRVS's performance, which depends on clinical trial results, helps to assess it as a high-risk asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Corvus is a biopharmaceutical company developing cancer treatments. Oncology is a highly volatile sector driven by clinical trial results. The chart below shows the average fluctuations in this industry, providing context for evaluating Corvus shares.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization CRVS
Corvus Pharmaceuticals' year-to-date performance is a story of the search for a breakthrough in immuno-oncology. Its market capitalization over the past 12 months reflects investors' faith in its unique approach to blocking adenosine receptors to stimulate anti-tumor immunity. Clinical trial data are a key factor determining its value.
Annual dynamics of market capitalization of the market segment - Cancer lymphonodes
Corvus Pharmaceuticals, Inc. is a clinical-stage biotech developing immunotherapy. Its stock performance is entirely dependent on clinical trial results. The chart reflects the high risks and potential for breakthroughs inherent in the biotech sector compared to big pharma.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Corvus Pharmaceuticals is a clinical-stage biotech whose fate depends on scientific breakthroughs, not the state of the economy. Its stock price reflects investor hopes for the success of new drug trials. The company's chart exists in a world of its own, where the main events are data releases.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization CRVS
The performance of Corvus, a biopharmaceutical company, is speculative. Monthly fluctuations on the chart reflect not revenue, but rather news about the progress of clinical trials of its innovative oncology drugs, the success of which determines its future and partnerships with major pharmaceutical companies.
Monthly dynamics of market capitalization of the market segment - Cancer lymphonodes
Corvus Pharmaceuticals is a clinical-stage biotech company developing a new generation of immuno-oncology drugs that target specific mechanisms that cancer cells use to evade the immune system. The chart below illustrates the dynamics of the biotech sector, which is fraught with risks and potential breakthroughs.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Corvus Pharmaceuticals is a clinical-stage biotech company developing cancer treatments. Its shares are completely uncorrelated with the market. Their price is a bet on the success of scientific research. Any news from the lab or regulator can change the company's value several-fold in a single day, as the chart shows.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization CRVS
Corvus Pharmaceuticals is a biotech company developing immunotherapy for cancer treatment. Its weekly stock price is a roller coaster, driven by the release of clinical trial data. The chart reflects the high risks and hopes of the oncology field.
Weekly dynamics of market capitalization of the market segment - Cancer lymphonodes
Corvus, like the entire oncology immunotherapy sector, is extremely volatile. Weekly stock price fluctuations in this segment often reflect broader scientific breakthroughs or setbacks, which impact investor interest in the entire field. The chart shows how the company is tracking this overall biotech trend.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Corvus Pharmaceuticals is a biotech company whose stock moves in sync with clinical trial news. This chart is a great way to see how its weekly fluctuations are disconnected from overall market trends. Is the company living its own life, or is it being affected by the global sell-off?
Market capitalization of the company, segment and market as a whole
CRVS - Market capitalization of the company CRVS
Corvus Pharmaceuticals' market capitalization is a visualization of the risks in drug development. This biotech company's chart reflects investor hopes for its innovative approaches in immuno-oncology. Its volatile curve is a direct response to the results of early-stage clinical trials.
CRVS - Share of the company's market capitalization CRVS within the market segment - Cancer lymphonodes
Corvus Pharmaceuticals is a biopharmaceutical company whose market share and market capitalization reflect investor valuation of its portfolio of immuno-oncology drugs in various stages of clinical development.
Market capitalization of the market segment - Cancer lymphonodes
Corvus Pharmaceuticals is developing cancer immunotherapy. How big is this arena? The chart below shows the pulse of the oncology biotech sector. Its dynamics map the hopes and disappointments in the search for new ways to harness the immune system to attack tumors.
Market capitalization of all companies included in a broad market index - GURU.Markets
The Corvus Pharmaceuticals chart shows how the market values innovative approaches in immuno-oncology. The company's market cap reflects a venture bet on the success of its molecules, which target new mechanisms to fight cancer. The chart's dynamics illustrate the high risk and potentially enormous reward of early-stage biotech.
Book value capitalization of the company, segment and market as a whole
CRVS - Book value capitalization of the company CRVS
For Corvus Pharmaceuticals, a biotech company, book value is its tangible assets: laboratories, scientific equipment, and financial reserves for conducting clinical trials in immuno-oncology. The chart below shows how the company built its physical foundation for scientific research.
CRVS - Share of the company's book capitalization CRVS within the market segment - Cancer lymphonodes
Corvus Pharmaceuticals is a biotech company whose tangible assets are research laboratories equipped with cutting-edge equipment for developing innovative immuno-oncology drugs. The chart shows the company's control over this specialized R&D infrastructure in its narrow but promising niche.
Market segment balance sheet capitalization - Cancer lymphonodes
Corvus Pharmaceuticals is an oncology company. Pharmaceuticals, as the chart shows, are both knowledge- and capital-intensive. Corvus focuses on drug development, and its capital is intellectual property and R&D infrastructure for clinical trials.
Book value of all companies included in the broad market index - GURU.Markets
Corvus Pharmaceuticals' balance sheet represents the value of its laboratories and R&D centers, where small molecules for immuno-oncology are developed. The chart shows how the company built its scientific and material foundation for the creation of new cancer treatments.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - CRVS
Corvus Pharma is a biotech company with laboratories. Its market valuation is a bet on their scientific approach to developing new cancer drugs. The chart shows how investors' faith in their scientific hypothesis has changed.
Market to book capitalization ratio in a market segment - Cancer lymphonodes
Corvus Pharmaceuticals is a clinical-stage biotech company developing cancer treatments. Its valuation is almost entirely dependent on research results. The chart shows how its market capitalization, based on expectations, compares to its current assets.
Market to book capitalization ratio for the market as a whole
Corvus Pharmaceuticals is a clinical-stage biotech developing cancer immunotherapy drugs. Its current valuation, compared to the average on this chart, is unrelated to its stock. It's a pure bet by investors that its unique approach to activating the immune system to fight tumors will prove successful.
Debts of the company, segment and market as a whole
CRVS - Company debts CRVS
Corvus Pharmaceuticals is a clinical-stage biotech company focused on immuno-oncology. This chart reflects its reliance on external funding. The company raises equity capital to support the development of its experimental drugs, and its future depends on the success of these clinical trials.
Market segment debts - Cancer lymphonodes
Corvus Pharmaceuticals is a clinical-stage biotech developing a new generation of immuno-oncology therapeutics. Its debt load reflects its need for capital to fund expensive clinical trials. This chart shows how the company raises funds to advance its drug candidates through the complex stages of development and testing.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio CRVS
Corvus Pharmaceuticals is a biotech company developing drugs to treat oncology. Its operations require significant investment in clinical research. This chart shows the extent to which the company relies on debt to finance its development, which is a measure of its financial risk on the long road to commercialization.
Market segment debt to market segment book capitalization - Cancer lymphonodes
Corvus Pharmaceuticals is a biotech company focused on developing immunotherapeutic drugs for cancer treatment. This chart shows the debt burden in the biotech sector. It is a key indicator of the company's ability to fund its expensive clinical research and development in this highly competitive field.
Debt to book value of all companies in the market
Corvus Pharmaceuticals is a clinical-stage biotech company developing immuno-oncology drugs. Without stable revenue, its survival depends on external funding. This graph of total market debt is an indicator of investor risk appetite, which directly impacts Corvus's ability to raise capital to continue research.
P/E of the company, segment and market as a whole
P/E - CRVS
Corvus Pharmaceuticals is a biotech company developing next-generation immuno-oncology drugs targeting innovative targets. This chart reflects the high risks and expectations associated with early-stage research. Its performance is entirely dependent on clinical trial data and investor confidence in the company's scientific approach.
P/E of the market segment - Cancer lymphonodes
Corvus Pharmaceuticals is a biotech company developing a new generation of immuno-oncology drugs. Its approach is based on modulating adenosine receptors to "turn on" the immune system to fight cancer. This chart shows the average valuation for the oncology sector, reflecting investor expectations for innovative approaches to cancer treatment.
P/E of the market as a whole
Corvus Pharmaceuticals is a biotech company developing cancer treatments. Its valuation is a pure bet on the success of its scientific hypotheses and clinical trials. Overall market sentiment, reflected in this chart, is completely irrelevant. Corvus's fate is decided in the lab and depends on the effectiveness of its drugs.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company CRVS
Corvus Pharmaceuticals is a biopharmaceutical company developing small-molecule drugs targeting the immune system for the treatment of cancer. This chart reflects expectations for its innovative approach to immuno-oncology. The company's valuation is a venture bet on the success of its clinical trials and potential partnerships with major pharmaceutical companies.
%20P%2FE%20CRVS&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-CRVS&v=1772652593207 "Chart of the company's future (projected) P/E CRVS")
Future (projected) P/E of the market segment - Cancer lymphonodes
Corvus Pharmaceuticals is a biotech company developing next-generation immunotherapeutic drugs for cancer treatment. Its valuation depends on the success of clinical trials. This chart reflects speculative investor expectations. Comparing its future revenue forecasts with the sector reveals the market's confidence in its scientific platform.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Cancer%20lymphonodes&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Cancer-lymphonodes&v=1772652593207 "Future (projected) P/E graph of the market segment - Cancer lymphonodes")
Future (projected) P/E of the market as a whole
Corvus Pharmaceuticals is a clinical-stage biotech focused on immuno-oncology. Its value is derived almost entirely from the expected future success of its drug candidates. This overall risk appetite curve is key, as it determines the availability of capital for the clinical trials necessary to bring the drugs to market.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772652593210 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit CRVS
Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on immuno-oncology. Its current financial results reflect expenditures on research and development of new drugs. Future profits are entirely dependent on successful clinical trials and subsequent commercialization.
Profit of companies in the market segment - Cancer lymphonodes
Corvus Pharmaceuticals develops innovative immuno-oncology therapies that target specific immune system mechanisms to fight cancer. The company operates in the highly competitive biopharma sector. This sector profitability chart reflects overall investor sentiment and the successes and failures of clinical trials, which drive capital inflows into the industry.
Overall market profit
Corvus Pharmaceuticals is a biotechnology company focused on developing innovative immuno-oncology drugs. Its research is aimed at activating the immune system to fight cancer. Corvus's potential success could lead to new treatments and demonstrates how the science-based sector is contributing to the future of healthcare and the economy.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company CRVS
Corvus Pharmaceuticals is a biotech company developing cancer immunotherapy drugs. This chart shows speculative expectations for its clinical trials. Future profits depend entirely on the success of its candidate molecules in treating various types of cancer.
%20profit%20of%20the%20company%20CRVS&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-CRVS&v=1772652593226 "Graph of future (projected) profit of the company CRVS")
Future (predicted) profit of companies in the market segment - Cancer lymphonodes
Corvus Pharmaceuticals is a biopharmaceutical company developing immuno-oncology drugs. This chart shows the projected profit trajectory for the biotech sector. This data allows us to assess how the company's innovative approach to cancer treatment meets the high expectations investors have for the industry.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Cancer%20lymphonodes&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Cancer-lymphonodes&v=1772652593226 "Graph of future (predicted) profits of companies in a market segment - Cancer lymphonodes")
Future (predicted) profit of the market as a whole
The profit outlook for Corvus Pharmaceuticals, a clinical-stage biotech, hinges on the success of its immuno-oncology developments. This chart reflects investor expectations for the results of its innovative drug trials. Any clinical data could dramatically alter the trajectory, as is typical in this sector.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772652593227 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - CRVS
Corvus Pharmaceuticals, a clinical-stage biopharmaceutical company focused on immuno-oncology, has virtually no product revenue. This chart shows a valuation based on investor expectations for its scientific developments. This represents the potential value of its pipeline, not a reflection of current financial performance.
P/S market segment - Cancer lymphonodes
Corvus Pharmaceuticals is a biotech company focused on developing immunotherapeutic drugs for the treatment of cancer. The company's valuation is based on the potential of its scientific developments. This chart shows the average valuation in the biotech industry, reflecting investor expectations for future revenue from Corvus's pipeline if they are successfully launched.
P/S of the market as a whole
Corvus Pharmaceuticals is a biotech company developing next-generation immuno-oncology drugs. The company has no commercial products and its revenue is minimal. This chart, showing Corvus's average revenue estimate, highlights that its valuation is a bet on the success of its research and future clinical trials.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company CRVS
Corvus Pharmaceuticals is a biotech company focused on immuno-oncology. It develops drugs that target the immune system to combat cancer. This chart reflects investor expectations for the future. It shows the market's assessment of the likelihood of success in its clinical trials and the potential of its scientific approach.
%20P%2FS%20CRVS&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-CRVS&v=1772652593252 "The graph of the company's future (projected) P/S CRVS")
Future (projected) P/S of the market segment - Cancer lymphonodes
Corvus Pharmaceuticals is a biopharmaceutical company developing immuno-oncology drugs. This chart compares market expectations for its future revenue with those of other companies working in the lymphoma treatment field. This valuation reflects investor confidence in its innovative approaches to modulating the immune system to fight cancer.
%20P%2FS%20market%20segment%20graph%20-%20Cancer%20lymphonodes&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Cancer-lymphonodes&v=1772652593256 "Future (projected) P/S market segment graph - Cancer lymphonodes")
Future (projected) P/S of the market as a whole
Corvus Pharmaceuticals is a biotech company developing immunotherapeutic drugs for cancer treatment. Its future, like that of many companies in this sector, depends on the results of clinical trials. Corvus's potential to develop new treatments is part of the overall optimism surrounding medical innovation, reflected in this chart.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772652593257 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales CRVS
Corvus Pharmaceuticals is a biopharmaceutical company developing innovative immuno-oncology therapies. While in clinical trials, the company may not generate sales revenue. This chart shows revenue from licensing agreements or future commercialization of its developments.
Sales of companies in the market segment - Cancer lymphonodes
Corvus Pharmaceuticals is a biopharmaceutical company developing innovative cancer immunotherapy drugs. Its approach is to target new immune system targets to fight tumors. This chart shows overall pharmaceutical sales, illustrating the rapid development and growth of the field of oncoimmunology, where Corvus is seeking its breakthrough.
Overall market sales
Corvus Pharmaceuticals is an early-stage biotech focused on developing immuno-oncology drugs. This overall economic activity schedule is important for Corvus because it impacts the availability of venture capital and the willingness of large pharma companies to partner, which is vital for small biotechs.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company CRVS
Corvus Pharmaceuticals is a clinical-stage biotechnology company developing innovative cancer immunotherapy drugs. Its future revenue is entirely dependent on successful clinical trial results and subsequent approval of its drugs. This chart reflects analysts' speculative expectations regarding the scientific and commercial potential of its developments.
%20sales%20of%20the%20company%20CRVS&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-CRVS&v=1772652593259 "Schedule of future (projected) sales of the company CRVS")
Future (projected) sales of companies in the market segment - Cancer lymphonodes
Corvus Pharmaceuticals is a biotech company developing immuno-oncology drugs. This chart shows projected revenues for the entire biotech sector. It reflects overall investment sentiment in the industry, but for Corvus, the success of clinical trials for its targeted cancer therapies is crucial.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Cancer%20lymphonodes&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Cancer-lymphonodes&v=1772652593261 "Schedule of future (projected) sales of companies in the market segment - Cancer lymphonodes")
Future (projected) sales of the market as a whole
Corvus Pharmaceuticals is a clinical-stage biotech focused on developing immuno-oncology drugs. Its valuation depends on the results of its research and the potential of its drug candidates. This graph, reflecting the overall economic situation, influences investors' risk appetite, which is critical for funding biotech companies that do not yet have stable revenues.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772652593272 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality CRVS
Corvus Pharmaceuticals is a biotech company developing immuno-oncology drugs. This chart for the clinical-stage company illustrates its financial strategy. It shows how Corvus manages its significant research expenses in pursuit of a breakthrough drug that will ensure future profitability.
Market segment marginality - Cancer lymphonodes
Corvus Pharmaceuticals is a biotech company developing next-generation immuno-oncology drugs. Its goal is to create innovative cancer treatments. This chart reflects its operational structure during clinical trials. It highlights the high R&D costs typical of biotech companies striving for medical breakthroughs.
Market marginality as a whole
Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company developing immuno-oncology drugs. Its future profitability depends on the success of its clinical trials and its ability to bring new cancer treatments to market. This total market profitability chart serves as a contrast to biotech, where scientific innovation, not economic cycles, determines ultimate success.
Employees in the company, segment and market as a whole
Number of employees in the company CRVS
Corvus Pharmaceuticals is a biotech company developing a new generation of immuno-oncology drugs. This graph shows a small, focused team of scientists. The size of the team reflects the early stage of development. Significant growth is only possible through successful clinical trials and a partnership with a major pharmaceutical company.
Share of the company's employees CRVS within the market segment - Cancer lymphonodes
This indicator reflects Corvus Pharmaceuticals' scientific approach. The company's oncology team is focused on developing a new class of drugs that target the adenosine pathway, which tumors use to suppress the immune system. This team of scientists strives to "unlock" the body's immune response to fight cancer.
Number of employees in the market segment - Cancer lymphonodes
Corvus Pharmaceuticals is a biopharmaceutical company focused on developing innovative immuno-oncology drugs. Its approaches are aimed at overcoming resistance to existing therapies. This graph illustrates the depth of scientific research in modern oncology, where companies like Corvus are exploring new avenues to fight cancer, attracting top scientists.
Number of employees in the market as a whole
Corvus Pharmaceuticals, Inc. is a biotech company developing immuno-oncology drugs. Its success depends on scientific discoveries and clinical trial results, not on the economic cycles reflected in this chart. The company is at the forefront of the fight against cancer, where value is created in the laboratory.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company CRVS (CRVS)
Corvus Pharmaceuticals is a biotech company working in the field of immuno-oncology. This chart shows a speculative valuation of its scientific potential. The very high market capitalization per scientist indicates that investors are placing their faith not in current results, but in a future breakthrough for one of its experimental drugs, which could be worth billions.
%20of%20the%20company%20CRVS%20(CRVS)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-CRVS-CRVS&v=1772652593320 "Chart of market capitalization per employee (in thousands of dollars) of the company CRVS (CRVS)")
Market capitalization per employee (in thousands of dollars) in the market segment - Cancer lymphonodes
Corvus Pharmaceuticals is developing next-generation immuno-oncology drugs. In biotech, this indicator reflects the market's confidence in the scientific platform. The graph demonstrates the enormous potential value investors see in the developments created by the team of scientists, even if the drugs are still in the early stages of research.
%20by%20market%20segment%20-%20Cancer%20lymphonodes&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Cancer-lymphonodes&v=1772652593321 "Market capitalization per employee (in thousands of dollars) by market segment - Cancer lymphonodes")
Market capitalization per employee (in thousands of dollars) for the overall market
Corvus Pharmaceuticals is a clinical-stage biotech company developing immuno-oncology drugs. This chart shows a high valuation per employee, which is typical for R&D companies. The value is derived from the potential of its scientific developments and intellectual property, not from current sales.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772652593321 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company CRVS (CRVS)
Corvus Pharmaceuticals is a clinical-stage biotech developing cancer therapies (specifically, lymphoma). The company is unprofitable. This chart shows the net loss (R&D costs) per scientist. It's a classic venture capital story, with the entire team working on a single, future breakthrough drug.
%20Chart%20CRVS%20(CRVS)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-CRVS-CRVS&v=1772652593322 "Company Profit Per Employee (in thousands of dollars) Chart CRVS (CRVS)")
Profit per employee (in thousands of dollars) in the market segment - Cancer lymphonodes
Corvus Pharmaceuticals is a biotech company working in the field of immuno-oncology. It develops small molecules that target the immune system to fight cancer. This chart shows the loss per employee during the R&D phase. It serves as a benchmark for assessing how intensively Corvus invests in R&D per scientist compared to its competitors in this high-tech race.
%20in%20the%20market%20segment%20-%20Cancer%20lymphonodes&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Cancer-lymphonodes&v=1772652593325 "Chart of profit per employee (in thousands of dollars) in the market segment - Cancer lymphonodes")
Profit per employee (in thousands of dollars) for the market as a whole
Corvus Pharmaceuticals (CRVS) is a clinical-stage biotech company working in the oncology field, focusing on small molecule and antibody development. This chart shows the company's per-employee loss, which is typical for R&D businesses. It reflects how much the company spends on scientists and clinical trials per employee, in the hopes of a future breakthrough.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772652593335 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee CRVS (CRVS)
Corvus Pharmaceuticals is a biotech company developing immuno-oncology drugs. This chart reflects the company's activities in the clinical trials stage. Revenue per employee is minimal and depends on grants or partnerships, with the primary value being generated in the laboratory and clinical trials.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-CRVS-CRVS&v=1772652593342 "Sales chart per company employee CRVS (CRVS)")
Sales per employee in the market segment - Cancer lymphonodes
Corvus Pharmaceuticals is a biotech company developing immunotherapeutic drugs for cancer treatment. This chart shows the average revenue per employee in the segment. As with other clinical-stage biotechs, it serves as a benchmark for performance in a sector where revenue is volatile and dependent on R&D success.
Sales per employee for the market as a whole
Corvus Pharmaceuticals is a clinical-stage biotech company specializing in immuno-oncology. They have no commercial products. This figure would be zero. Their entire staff (scientists) is focused on research and development of new approaches to cancer treatment, and funding comes from investors, not sales.
Short shares by company, segment and market as a whole
Shares shorted by company CRVS (CRVS)
Corvus Pharmaceuticals is a biotech company focused on immuno-oncology. The bearish sentiment seen in this chart reflects investor skepticism about its R&D candidates. These bears are betting on clinical trial failure, which is typical for the speculative biotech sector with high capital burn.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-CRVS-CRVS&v=1772652593346 "Short Shares Chart for the Company CRVS (CRVS)")
Shares shorted by market segment - Cancer lymphonodes
Corvus Pharmaceuticals is a clinical-stage biotech company developing next-generation immunotherapeutic drugs for cancer treatment. This chart reflects the overall sentiment in the sector. It reflects investor skepticism toward biotech startups in oncology, where competition is fierce and the risk of clinical failure is highest.
Shares shorted by the overall market
Corvus is a clinical-stage biotech company focused on oncology. Its value is based on future expectations. When this market fear indicator rises, investors' risk appetite evaporates. They are the first to sell speculative, loss-making biotechs like CRVS in favor of safer assets that generate profits here and now.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator CRVS (CRVS)
Corvus Pharmaceuticals (CRVS) is a biotech company developing drugs to treat cancer, particularly T-cell lymphoma, and immunological diseases. This chart measures hype. It shows "overheated" (above 70) due to positive clinical trial data or "oversold" (below 30) amid delays or setbacks, which is typical for the biotech sector.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-CRVS-CRVS&v=1772652593348 "RSI 14 indicator chart for the company's stock CRVS (CRVS)")
RSI 14 Market Segment - Cancer lymphonodes
Corvus Pharmaceuticals (CRVS) is a biotech company developing immuno-oncology drugs. They are exploring new ways to harness the immune system to fight cancer. This chart measures overall sentiment in the Oncology sector. It helps distinguish Corvus's trial successes from general overheating or overselling across the biotech sector.
RSI 14 for the overall market
Corvus (CRVS) is a biotech company. Like everything in its sector, it's critically dependent on this chart. Market euphoria is an easy way to raise hundreds of millions of dollars for research. Market panic is the risk of running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast CRVS (CRVS)
Corvus Pharmaceuticals (CRVS) is a clinical-stage biopharmaceutical company developing immunotherapeutics. Its lead candidate, mupadolimab, targets a new immune pathway for cancer treatment. This chart shows the average Wall Street forecast, reflecting analysts' assessments of the early clinical data and potential of this innovative target.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-CRVS-CRVS&v=1772652593370 "A chart showing analyst consensus forecasts for the expected stock price. CRVS (CRVS)")
The difference between the consensus estimate and the actual stock price CRVS (CRVS)
Corvus Pharmaceuticals (CRVS) is an oncology company developing immunotherapies (including CPI-818) for the treatment of T-cell lymphomas. This chart is a barometer of their R&D. It measures the gap between the price and the consensus target, reflecting the high, yet speculative, potential analysts see in their clinical programs.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-CRVS-CRVS&v=1772652593373 "A chart showing the difference between the consensus forecast and the actual stock price. CRVS (CRVS)")
Analyst consensus forecast for stock prices by market segment - Cancer lymphonodes
Corvus Pharmaceuticals is a biotech company developing a new generation of immunotherapy. Its R&D pipeline is focused on the treatment of T-cell lymphomas and other complex cancers. This chart shows analysts' overall expectations across the oncology sector, reflecting whether experts believe new approaches to treating blood cancers are successful.
Analysts' consensus forecast for the overall market share price
Corvus Pharmaceuticals is a biotech company developing cancer immunotherapy drugs, specifically those targeting novel mechanisms (adenosine) for the treatment of lymphoma. This chart shows the overall risk appetite. For Corvus, a clinical-stage company, overall market optimism is critical to attracting the capital needed to fund long-term research.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index CRVS
Corvus (CRVS) is a clinical-stage biotech focused on immuno-oncology. They are developing a new generation of drugs that harness the immune system to fight cancer. This graph represents pure R&D. Its valuation reflects the market's faith in their scientific platform (especially their approach to adenosine) and their early clinical trial data.
AKIMA Market Segment Index - Cancer lymphonodes
Corvus (CRVS) is a clinical-stage biotech focused on cancer immunotherapy; the company is developing innovative drugs (including CD73 inhibitors) for the treatment of various cancers. This summary metric evaluates R&D. The graph shows the segment average. This is a benchmark: how does this R&D rate (CRVS) differentiate it from the average pharma company?
The AKIM Index for the overall market
Corvus Pharmaceuticals is a biotech company developing immunotherapies for cancer and immune diseases that target myeloid cells. This chart, which reflects the market average, provides a macro backdrop. It helps assess how this speculative scientific story, fueled by clinical trial data, compares to overall economic trends.
